Inspire Medical Systems, Inc. cash flow to debt ratio of 363.79% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Inspire Medical Systems, Inc.'s free cash flow has decreased 13.88% from $91.12M last year to $78.48M, signaling decreasing performance

Inspire Medical Systems, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Inspire Medical Systems, Inc.'s debt has decreased relative to shareholder equity from 0.05 last year to 0.04 today, signaling strengthened financials

Inspire Medical Systems, Inc. has a net cash position, so leverage is healthy.

Inspire Medical Systems, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Inspire Medical Systems, Inc.'s profit margin has increased (125.43%) in the last year from 6.67% to 15.03%, signaling increasing performance

Inspire Medical Systems, Inc.'s short-term assets of $583.65M exceed its short-term liabilities of $96.06M

Inspire Medical Systems, Inc.'s return on assets of 14.58% is higher than the 5.00% threshold, indicating efficient asset utilization

Inspire Medical Systems, Inc.'s return on equity of 17.62%, is higher than 15.00%, indicating good performance

Inspire Medical Systems, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Inspire Medical Systems, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Inspire Medical Systems, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Inspire Medical Systems, Inc. has a free cash flow yield of 4.55%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Inspire Medical Systems, Inc.'s yearly earnings has increased 171.77% since last year from $53.51M to $145.42M, signaling increasing performance

Inspire Medical Systems, Inc.'s yearly revenue has increased 13.60% since last year from $802.80M to $911.98M, signaling increasing performance

ROIC 6.33% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Inspire Medical Systems, Inc.'s 3-year revenue CAGR of 30.77% is positive, indicating growing revenue over the past 3 years

Inspire Medical Systems, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Inspire Medical Systems, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Inspire Medical Systems, Inc. has insufficient data to evaluate this check.

Inspire Medical Systems, Inc. has an earnings yield of 7.84%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Inspire Medical Systems, Inc. is overvalued relative to its fair value price of 18.31 based on EBITDA multiple model

Inspire Medical Systems, Inc. has an EV/EBITDA ratio of 18.18x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Inspire Medical Systems, Inc. is overvalued relative to its fair value price of -38.23 based on Earnings Fair Value model

Inspire Medical Systems, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Inspire Medical Systems, Inc. has a price-to-book ratio of 2.09x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Inspire Medical Systems, Inc. has a price-to-sales ratio of 1.92x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue